Impact BioMedical experienced a severe cash depletion from $2.0M to $3K while substantially reducing operating losses and liabilities.
The company's cash position collapsed to just $3K, creating an immediate liquidity crisis that threatens operations despite meaningful improvements in loss reduction. While the company substantially reduced operating losses and eliminated significant liabilities, the near-zero cash position suggests urgent need for additional financing or potential going-concern issues.
The company's financial profile shows a dramatic cash depletion alongside substantial debt reduction and meaningful operating loss improvements. Current liabilities dropped significantly from $9.8M to $1.2M, while operating losses improved considerably from -$28.8M to -$4.3M, indicating better expense control. However, the collapse in cash reserves to just $3K, combined with minimal revenue of $32K, creates severe near-term liquidity constraints that overshadow the operational improvements.
Cash declined 99.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current liabilities reduced — improved short-term financial position and working capital health.
Liabilities reduced 85.8% — deleveraging improves balance sheet strength and financial flexibility.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Current assets declined 83.2% — monitor working capital adequacy and short-term liquidity.
Net income grew 52.1% — bottom-line growth signals improving overall business health.
Operating cash flow surged 51.8% — exceptional cash generation, highest quality earnings signal.
Revenue declined 36% — significant demand weakness or market share loss warrants investigation.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
R&D investment increased 22.3% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →